FXN methylation predicts expression and clinical outcome in Friedreich ataxia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Friedreich ataxia (FA) is the most common ataxia and results from an expanded GAA repeat in the first intron of FXN. This leads to epigenetic modifications and reduced frataxin. We investigated the relationships between genetic, epigenetic, and clinical parameters in a large case–control study of FA. Methods: Clinical data and samples were obtained from individuals with FA during annual visits to our dedicated FA clinic. GAA expansions were evaluated by polymerase chain reaction (PCR) and restriction endonuclease digest. DNA methylation was measured using bisulfite‐based EpiTYPER MassARRAY (Sequenom, San Diego, CA). FXN expression was determined using real‐time reverse transcriptase PCR. Significant correlations between the different parameters were examined using the nonparametric Spearman rank correlation coefficient, as well as univariate and multivariate regression modeling. Results: Characteristic DNA methylation was identified upstream and downstream of the expansion, and validated in an independent FA cohort. Univariate and multivariate analyses showed significant inverse correlations between upstream methylation and FXN expression, and variation in downstream methylation and age of onset. FXN expression also inversely correlated with the Friedreich Ataxia Rating Scale score, an indicator of disease severity. Interpretation: These novel findings provide compelling evidence for the link between the GAA expansion, the DNA methylation profile, FXN expression, and clinical outcome in FA. Epigenetic profiling of FXN could be used to gain greater insight into disease onset and progression, but also as a biomarker to learn more about specific treatment responses and pharmacological mechanism(s). This work also highlights the potential for developing therapies aimed at increasing frataxin levels to treat this debilitating disease. ANN NEUROL 2012;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bird, A. (2007) · Nature · doi:10.1038/nature05913 · Cited by 3,011 · cited 1×
“Epigenetics encompasses a range of regulatory modifications that alter DNA, without changing its primary sequence.(1) This includes regulating expression of many genes through variations in their epigenetic profile.”
BackgroundEpigenomic Profiling Reveals DNA-Methylation Changes Associated with Major Psychosis
Mill, J., Tang, T., Kaminsky, Z., Khare, T., Yazdanpanah, S., Bouchard, L., Jia, P., Assadzadeh, A., Flanagan, J., Schumacher, A., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.008 · Cited by 773
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442 · cited 1×
“It is an inhibitor of HDAC-3 that increased FXN levels in human FA cell lines and an FA mouse model.(24,25,51) Gene and cellular therapies aimed at restoring FXN expression are also in development.”
BackgroundSelf-citationBidichandani, S. I., Ashizawa, T., & Patel, P. I. (1998) · The American Journal of Human Genetics · doi:10.1086/301680 · Cited by 381
Mechanisms of disease: the developmental origins of disease and the role of the epigenotype
Ozanne, S. E., & Constância, M. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0531 · Cited by 232 · cited 1×
“It is well established that chromatin remodeling and increased methylation of promoter CpG islands are associated with silencing of gene expression.(20,43,44) The GAA expansion undergoes chromatin remodeling,(23,45) and differential methylation of the PRO region has been reported in heart and brain tissues from 2 indi…”
BackgroundHuang, M. L.-H., Becker, E. M., Whitnall, M., Rahmanto, Y. S., Ponka, P., & Richardson, D. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906784106 · Cited by 212
Cited by
Tandem repeats mediating genetic plasticity in health and disease
Hannan, A. J. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.115 · Cited by 446
Hypermethylation of the CpG Island Near the G4C2 Repeat in ALS with a C9orf72 Expansion
Xi, Z., Zinman, L., Moreno, D., Schymick, J., Liang, Y., Sato, C., Zheng, Y., Ghani, M., Dib, S., Keith, J., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.017 · Cited by 266
Friedreich Ataxia: Neuropathology Revised
Koeppen, A. H., & Mazurkiewicz, J. E. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827e5762 · Cited by 261
on behalf of the BELNEU CONSORTIUM, Gijselinck, I., Van Mossevelde, S., van der Zee, J., Sieben, A., Engelborghs, S., De Bleecker, J., Ivanoiu, A., Deryck, O., Edbauer, D., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.159 · Cited by 242
Friedreich’s ataxia: clinical features, pathogenesis and management
Cook, A., & Giunti, P. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx034 · Cited by 215
“This methylation is inversely correlated with FXN expression and age of onset of disease, suggesting an important role in pathogenesis of the disease.(29) Similar biochemical modifications of histones have been shown to modulate the chromatin structure and thus the transcriptional availability of genes.”
Background
Metadata
- Authors
- Evans‐Galea, M. V., Carrodus, N., Rowley, S. M., Corben, L. A., Tai, G., Saffery, R., Galati, J. C., Wong, N. C., Craig, J. M., Lynch, D. R., Regner, S. R., Brocht, A. F. D., Perlman, S. L., Bushara, K. O., Gomez, C. M., Wilmot, G. R., Li, L., Varley, E., Delatycki, M. B., & Sarsero, J. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-04
- Volume
- 71
- Issue
- 4
- Pages
- 487-497
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1986826633
- Cited by
- 119
- References
- 6
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.